TY - JOUR T1 - Development of a core outcome set for multimorbidity trials in low- and middle-income countries (COSMOS): Study Protocol JF - medRxiv DO - 10.1101/2021.03.23.21253685 SP - 2021.03.23.21253685 AU - Jan R. Boehnke AU - Rusham Zahra Rana AU - Jamie J. Kirkham AU - Louise Rose AU - Gina Agarwal AU - Corrardo Barbui AU - Alyssa Chase AU - Rachel Churchill AU - Oscar Flores-Flores AU - John R. Hurst AU - Naomi Levitt AU - Josefien van Olmen AU - Marianna Purgato AU - Kamran Siddiqi AU - Eleonora Uphoff AU - Rajesh Vedanthan AU - Judy Wright AU - Kath Wright AU - Gerardo A. Zavala AU - Najma Siddiqi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/30/2021.03.23.21253685.abstract N2 - Introduction ‘Multimorbidity’ describes the presence of two or more long-term conditions, which can include communicable and non-communicable diseases, and mental disorders. The rising global burden from multimorbidity is well-documented, but trial evidence for effective interventions in low- and middle-income countries (LMICs) is limited. Selection of appropriate outcomes is fundamental to trial design to ensure cross-study comparability, but there is currently no agreement on a core outcome set (COS) to include in trials investigating multimorbidity specifically in LMIC. Our aim is to develop international consensus on two COS for trials of interventions to prevent and treat multimorbidity in LMIC settings.Methods and Analysis Following methods recommended by the Core Outcome Measures in Effectiveness Trials (COMET initiative), the development of these two COS will occur in three stages: (1) generation of a long list of potential outcomes for inclusion; (2) two-round online Delphi surveys; and (3) consensus meetings. First, to generate an initial list of outcomes, we will conduct a systematic review of multimorbidity intervention and prevention trials and interviews with people living with multimorbidity and their caregivers in LMICs. Outcomes will be classified using an outcome taxonomy. Two-round Delphi surveys will be used to elicit importance scores for these outcomes from people living with multimorbidity, caregivers, healthcare professionals, policy makers, and researchers in LMICs. Finally, consensus meetings will be held to discuss the Delphi survey results and agree outcomes for inclusion in the two COS.Ethics and dissemination The study has been approved by the Research Governance Committee of the Department of Health Sciences, University of York, UK [HSRGC/2020/409/D:COSMOS]. Each participating country/research group will obtain local ethics board approval. Informed consent will be obtained from all participants. We will disseminate findings through peer-reviewed open access publications, and presentations at global conferences selected to reach a wide range of LMIC stakeholders.Trial registration PROSPERO ID CRD42020197293COMET https://www.comet-initiative.org/Studies/Details/1580Strengths and limitations of this studyThe development process follows guidelines and best practice recommendations for developing core outcome sets and integrates four sources of information.Interviews with people living with multimorbidity and caregivers are conducted in several LMICs (in South Asia, Africa and Latin America), by local teams, and in local languages to identify outcomes relevant to them.The Delphi survey and consensus meetings are conducted in English which limits the breadth of participation in these stages of the process.Despite involvement of a wide range of LMIC stakeholders in the process, there may be some limitations to the generalisability of the final core outcome sets due to the heterogeneity of target conditions and the diversity of countries, cultures and experiences.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.comet-initiative.org/Studies/Details/1580 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=197293 Funding StatementDeclaration of funding and other support: This research is supported in part by the National Institute for Health Research (NIHR) using Official Development Assistance (ODA) funding (Grant: 17/63/130: NIHR Global Health Research Group: Improving Outcomes in Mental and Physical Multimorbidity and Developing Research Capacity (IMPACT) in South Asia at the University of York). The research is also receiving support from Bradford District Care NHS Foundation Trust and a NIHR Global Health Research Short Placement Award for Research Collaboration to Rusham Zahra Rana (SPARC PILOT 01-19-03). Oscar Flores-Flores is supported by the Research Training in Chronic, non-communicable respiratory diseases in Peru, Fogarty International Center, US National Institutes of Health (D43TW011502). The core outcome set development is also supported by the Global Alliance for Chronic Diseases (GACD) Multimorbidity Working Group; the World Psychiatry Association; and by Cochrane Common Mental Disorders which is funded by NIHR (NIHR 129457) and Cochrane Global Mental Health (https://globalmentalhealth.cochrane.org). It is supported by the NCD Alliance by dissemination of participation opportunities to people living with multiple health conditions in its network.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Research Governance Committee of the Department of Health Sciences, University of York, UK [HSRGC/2020/409/D:COSMOS]. Each participating country/research group will obtain local ethics board approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe submitted manuscript is a protocol and has no attached data. ER -